Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sera Labs","sponsor":"CURE Pharmaceutical","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"$20.0 million","newsHeadline":"CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Applies for IND Number from the US Food and Drug Administration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Completes Pre-IND meeting with the U.S. Food & Drug Administration for JW-100 in the Treatment of Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Aspartame

    Menu

    Aspartame

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Safety Shot

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jupiter Wellness Completes Pre-IND meeting with the U.S. Food & Drug Administration for JW-100 in the Treatment of Eczema

              Details:

              JW-100 (cannabidiol), met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use.

              Lead Product(s): Cannabidiol,Aspartame

              Therapeutic Area: Dermatology Product Name: JW-100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Safety Shot

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jupiter Wellness Applies for IND Number from the US Food and Drug Administration

              Details:

              Jupiter Wellness previously reported that in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use.

              Lead Product(s): Cannabidiol,Aspartame

              Therapeutic Area: Dermatology Product Name: JW-100

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Safety Shot

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments

              Details:

              Jupiter Wellness commenced patient enrollment for skin cancer. Jupiter's JW-200 is designed to provide action and relief in the treatment of eczema, Actinic Keratosis, the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays.

              Lead Product(s): Cannabidiol,Aspartame

              Therapeutic Area: Dermatology Product Name: JW-100

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sera Labs

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction

              Details:

              Acquisition of Sera Labs will add to CURE a growing brand portfolio and monetization platform that fits remarkably well with CURE’s development capabilities, products, and existing market verticals.

              Lead Product(s): Cannabidiol,Aspartame

              Therapeutic Area: Dermatology Product Name: Seratopical

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: CURE Pharmaceutical

              Deal Size: $44.0 million Upfront Cash: $20.0 million

              Deal Type: Acquisition July 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY